During the last session, Gain Therapeutics Inc (NASDAQ:GANX)’s traded shares were 0.35 million, with the beta value of the company hitting 0.34. At the end of the trading day, the stock’s price was $2.32, reflecting an intraday loss of -7.20% or -$0.18. The 52-week high for the GANX share is $5.33, that puts it down -129.74 from that peak though still a striking 61.64% gain since the share price plummeted to a 52-week low of $0.89. The company’s market capitalization is $59.24M, and the average intraday trading volume over the past 10 days was 0.31 million shares, and the average trade volume was 398.81K shares over the past three months.
Gain Therapeutics Inc (GANX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. GANX has a Sell rating from 0 analyst(s) out of 13 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 12 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.21.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Gain Therapeutics Inc (NASDAQ:GANX) trade information
Gain Therapeutics Inc (GANX) registered a -7.20% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -7.20% in intraday trading to $2.32, hitting a weekly high. The stock’s 5-day price performance is -12.45%, and it has moved by 34.88% in 30 days. Based on these gigs, the overall price performance for the year is -19.16%. The short interest in Gain Therapeutics Inc (NASDAQ:GANX) is 0.57 million shares and it means that shorts have 1.6 day(s) to cover.
The consensus price target of analysts on Wall Street is $7, which implies an increase of 66.86% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $4 and $10 respectively. As a result, GANX is trading at a discount of -331.03% off the target high and -72.41% off the low.
Gain Therapeutics Inc (GANX) estimates and forecasts
Statistics show that Gain Therapeutics Inc has outperformed its competitors in share price, compared to the industry in which it operates. Gain Therapeutics Inc (GANX) shares have gone down -21.62% during the last six months, with a year-to-date growth rate more than the industry average at 38.60% against 18.10. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 43.20% this quarter and then jump 41.70% in the quarter after that. In the rating firms’ projections, revenue will decrease -45.50% compared to the previous financial year.
Meanwhile, a consensus of 3 analyst(s) estimates revenue growth to 30k by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -79.01%. While earnings are projected to return 39.41% in 2024.
GANX Dividends
Gain Therapeutics Inc is due to release its next quarterly earnings on 2024-Nov-12. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Gain Therapeutics Inc (NASDAQ:GANX)’s Major holders
Gain Therapeutics Inc insiders own 5.09% of total outstanding shares while institutional holders control 11.92%, with the float percentage being 12.56%. TIMELO INVESTMENT MANAGEMENT INC. is the largest shareholder of the company, while 32.0 institutions own stock in it. As of 2024-06-30, the company held over 0.61 million shares (or 3.3666% of all shares), a total value of $0.77 million in shares.
The next largest institutional holding, with 0.57 million shares, is of DME CAPITAL MANAGEMENT, LP’s that is approximately 3.1488% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $0.72 million.
